Safety and efficacy of sertraline for depression in patients with CHF (SADHART-CHF): a randomized, double-blind, placebo-controlled trial of sertraline for major depression with congestive heart failure.
BACKGROUND: Sertraline, a selective serotonin-reuptake inhibitor, has demonstrated substantial mood improvement in patients with post myocardial infarction or with unstable angina. The impact of sertraline on the prognosis and depression of patients with chronic heart failure (HF) and comorbid major depressive disorder (MDD) is unknown. METHOD: This is a prospective, randomized, double-blind, placebo-controlled study designed to assess the safety and efficacy of sertraline in the treatment of MDD in patients with HF. The study is designed also to examine the effects of treating depression on cardiac events and morbidity/mortality in patients with HF. Approximately 500 men and women who are >or=45 years of age with current MDD and chronic systolic HF, characterized by left ventricular ejection fraction
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Sertraline
- Research Design
- Humans
- Heart Failure
- Double-Blind Method
- Depression
- Cardiovascular System & Hematology
- Antidepressive Agents
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
Citation
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Sertraline
- Research Design
- Humans
- Heart Failure
- Double-Blind Method
- Depression
- Cardiovascular System & Hematology
- Antidepressive Agents
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services